Clinical Trials

121 enrolled

Lymphoma, Non-Hodgkin

NCT06252675 2026-04-20

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

30 enrolled

Lymphoma, Mantle-Cell

NCT07003295 2026-04-16

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

Lymphoma, Mantle-Cell

NCT06634589 2026-04-15

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT06090539 2026-04-14

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

308 enrolled

Lymphoma, Non-Hodgkin

NCT03075696 2026-04-03

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

940 enrolled 2 FDA

Lymphoma, Non-Hodgkin

NCT05533775 2026-04-03

iMATRIX GLO

65 enrolled

Recurrence

NCT07200375 2026-04-03

GlofitReal

Recruiting

300 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06084936 2026-04-02

GLOBRYTE

Phase 3 Recruiting

182 enrolled

Lymphoma

NCT06624085 2026-04-02

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

50 enrolled

Lymphoma

NCT06806033 2026-03-31

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06481826 2026-03-27

Glofitamab in Chinese Patients With R/R DLBCL

Recruiting

20 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT04889716 2026-03-18

CAR-T Followed by Bispecific Antibodies

42 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

200 enrolled

Lymphoma, B-Cell

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

43 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT06558604 2026-02-11

GLOASIS

100 enrolled

Lymphoma, Mantle-Cell

NCT06393738 2026-02-10

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

255 enrolled

Phase EARLY_PHASE1 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT04161248 2026-02-02

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

18 enrolled

Lymphoma, B-Cell

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

27 enrolled